{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"TMCI","limit":50},"count":50,"signals":[{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":14,"context":"g at the 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified; | | | To approve, on an advisory, non-binding basis, the compensation of our named executive officers; | | | To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; and | | | To transact such other busines","filed_date":"2026-04-06","accession":"0001630627-26-000005","full_text":"https://origin.rootz.global/static/filing/0001630627-26-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"ions, we currently have three prospective, multicenter, post-market studies underway: 1. the ALIGN3D clinical study designed to evaluate outcomes of the Lapiplasty Procedure, which has completed enrollment with 173 patients; 2. the MTA3D clinical study designed to evaluate outcomes of the combined Adductoplasty and Lapiplasty Procedures for patients in need of metatarsus adductus and hallux valgus","filed_date":"2026-02-27","accession":"0001193125-26-079167","full_text":"https://origin.rootz.global/static/filing/0001193125-26-079167.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":100,"context":"2025 has resulted and may continue to result in changes to or new legislation, regulations, policies, agency guidance, or executive orders that are difficult to predict, and such changes could have a material adverse impact on our business. Federal, State and Foreign Fraud and Abuse and Physician Payment Transparency Laws In addition to FDA restrictions on the marketing, promotion and sale of drugs, biologics and devic","filed_date":"2026-02-27","accession":"0001193125-26-079167","full_text":"https://origin.rootz.global/static/filing/0001193125-26-079167.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"1630627/000095017025051369/) **Origin leaf:** 42896978f292cbda3be4ae6350be113964da9e664bfba92291b9b0369f36a731 **Words:** 40,368 **Logo:** https://api.massive.com/v1/reference/company-branding/dHJlYWNlLmNvbQ/images/2025-04-04_logo.png --- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of","filed_date":"2025-04-07","accession":"0000950170-25-051369","full_text":"https://origin.rootz.global/static/filing/0000950170-25-051369.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":13,"context":"g at the 2028 annual meeting of stockholders and until their respective successors have been duly elected and qualified; | | | To approve, on an advisory, non-binding basis, the compensation of our named executive officers; | | | To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and | | | To transact such other busines","filed_date":"2025-04-07","accession":"0000950170-25-051369","full_text":"https://origin.rootz.global/static/filing/0000950170-25-051369.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":99,"context":"he federal administration in 2025 may result in changes to or new legislation, regulations, policies, agency guidance, or executive orders that are difficult to predict, and such changes could have a material adverse impact on our business. Federal, State and Foreign Fraud and Abuse and Physician Payment Transparency Laws In addition to FDA restrictions on the marketing, promotion and sale of drugs, biologics and devic","filed_date":"2025-02-27","accession":"0000950170-25-029029","full_text":"https://origin.rootz.global/static/filing/0000950170-25-029029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":20,"context":"ree-year term of office expiring at the 2027 annual meeting of stockholders and until their respective successors have been duly elected and qualified; 2. An advisory vote on the compensation of our named executive officers; 3. An advisory vote on the frequency of future advisory votes on the compensation of our named executive officers; 4. The ratification of the appointment of Grant Thornton LLP as our independent re","filed_date":"2024-04-02","accession":"0000950170-24-040228","full_text":"https://origin.rootz.global/static/filing/0000950170-24-040228.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"1630627/000095017024021228/) **Origin leaf:** d6a5ec645f2f4e9a18102467388d86567eff75a48f323435a4f346ebca56de7f **Words:** 76,148 **Logo:** https://api.massive.com/v1/reference/company-branding/dHJlYWNlLmNvbQ/images/2025-04-04_logo.png --- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) | | | | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECU","filed_date":"2024-02-27","accession":"0000950170-24-021228","full_text":"https://origin.rootz.global/static/filing/0000950170-24-021228.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":93,"context":"ies or other strategic alliances, and the failure to manage acquisitions, investments, licenses or other strategic alliances, or the failure to integrate them with our existing business, could have a material adverse effect on our operating results, dilute our stockholders' ownership, increase our debt or cause us to incur significant expense. Our relationships with customers, physicians and third-party payors are subj","filed_date":"2024-02-27","accession":"0000950170-24-021228","full_text":"https://origin.rootz.global/static/filing/0000950170-24-021228.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":35,"context":"ies or other strategic alliances, and the failure to manage acquisitions, investments, licenses or other strategic alliances, or the failure to integrate them with our existing business, could have a material adverse effect on our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense. • Our relationships with customers, physicians and third-party","filed_date":"2023-03-08","accession":"0000950170-23-006603","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006603.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":22,"context":"s in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably expected to have a material adverse effect on the business, properties, management, financial position, stockholders equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the","filed_date":"2023-02-10","accession":"0001193125-23-032511","full_text":"https://origin.rootz.global/static/filing/0001193125-23-032511.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":36,"context":"ies or other strategic alliances, and the failure to manage acquisitions, investments, licenses or other strategic alliances, or the failure to integrate them with our existing business, could have a material adverse effect on our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense. • Our relationships with customers, physicians and third-party","filed_date":"2022-03-04","accession":"0000950170-22-002903","full_text":"https://origin.rootz.global/static/filing/0000950170-22-002903.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":38,"context":"key suppliers, we may be unable to meet customer orders for our products in a timely manner or within our budget. | | | | | | We are subject to substantial government regulation that could have a material adverse effect on our business. | | **Our Corporate Information** We were originally formed as a medical device consulting business in July 2013, and began focusing on the foot and ankle market in January 2014. We","filed_date":"2021-04-19","accession":"0001193125-21-120293","full_text":"https://origin.rootz.global/static/filing/0001193125-21-120293.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":38,"context":"key suppliers, we may be unable to meet customer orders for our products in a timely manner or within our budget. | | | | | | We are subject to substantial government regulation that could have a material adverse effect on our business. | | ** 9 Table of Contents Our Corporate Information** We were originally formed as a medical device consulting business in July 2013, and began focusing on the foot and ankle mark","filed_date":"2021-03-30","accession":"0001193125-21-100296","full_text":"https://origin.rootz.global/static/filing/0001193125-21-100296.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"1630627/000095017025029029/) **Origin leaf:** ea0ff632835afb16f11f1d7d8927a2b6b12580fe701ae35042eee95438750d16 **Words:** 76,373 **Logo:** https://api.massive.com/v1/reference/company-branding/dHJlYWNlLmNvbQ/images/2025-04-04_logo.png --- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) | | | | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECU","filed_date":"2025-02-27","accession":"0000950170-25-029029","full_text":"https://origin.rootz.global/static/filing/0000950170-25-029029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"the future. We have experienced disruptions to our revenue and may experience further business disruptions, including disruptions to our supply chain, independent sales agents, customers, study enrollment timelines and regulatory processes. Further, patients continue to delay or forego bunion surgery procedures to avoid hospitals and ambulatory surgical centers and comply with quarantine and/or sim","filed_date":"2021-04-19","accession":"0001193125-21-120293","full_text":"https://origin.rootz.global/static/filing/0001193125-21-120293.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"the future. We have experienced disruptions to our revenue and may experience further business disruptions, including disruptions to our supply chain, independent sales agents, customers, study enrollment timelines and regulatory processes. Further, patients continue to delay or forego bunion surgery procedures to avoid hospitals and ambulatory surgical centers and comply with quarantine and/or sim","filed_date":"2021-03-30","accession":"0001193125-21-100296","full_text":"https://origin.rootz.global/static/filing/0001193125-21-100296.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"1630627/000095017023006603/) **Origin leaf:** 833ab25ebd2d9fa28e239669fcf75744818db8ac21bb73402ecbe46176440d2d **Words:** 72,688 **Logo:** https://api.massive.com/v1/reference/company-branding/dHJlYWNlLmNvbQ/images/2025-04-04_logo.png --- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) | | | | | | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH","filed_date":"2023-03-08","accession":"0000950170-23-006603","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006603.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"1630627/000095017022002903/) **Origin leaf:** 8533c47feffa2d6c63c9d20dc8caa0962ba8184d1af99aa6e9bbf67d6964c624 **Words:** 71,149 **Logo:** https://api.massive.com/v1/reference/company-branding/dHJlYWNlLmNvbQ/images/2025-04-04_logo.png --- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) | | | | | | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH","filed_date":"2022-03-04","accession":"0000950170-22-002903","full_text":"https://origin.rootz.global/static/filing/0000950170-22-002903.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":72,"match_count":9,"context":"he future, some of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in reduced demand for our products or additional pricing pressure. Federal, State and Foreign Fraud and Abuse and Physician Payment Transparency Laws In addition to FDA restrictions on the marketing, promotion and sale of drugs and devices, other federal and stat","filed_date":"2024-02-27","accession":"0000950170-24-021228","full_text":"https://origin.rootz.global/static/filing/0000950170-24-021228.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":72,"match_count":9,"context":"he future, some of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in reduced demand for our products or additional pricing pressure. Federal, State and Foreign Fraud and Abuse and Physician Payment Transparency Laws In addition to FDA restrictions on marketing and promotion of drugs and devices, other federal and state laws res","filed_date":"2023-03-08","accession":"0000950170-23-006603","full_text":"https://origin.rootz.global/static/filing/0000950170-23-006603.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":64,"match_count":8,"context":"he future, some of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in reduced demand for our products or additional pricing pressure. The change in the federal administration in 2025 has resulted and may continue to result in changes to or new legislation, regulations, policies, agency guidance, or executive orders that are diffic","filed_date":"2026-02-27","accession":"0001193125-26-079167","full_text":"https://origin.rootz.global/static/filing/0001193125-26-079167.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":64,"match_count":8,"context":"he future, some of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in reduced demand for our products or additional pricing pressure. The change in the federal administration in 2025 may result in changes to or new legislation, regulations, policies, agency guidance, or executive orders that are difficult to predict, and such chan","filed_date":"2025-02-27","accession":"0000950170-25-029029","full_text":"https://origin.rootz.global/static/filing/0000950170-25-029029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":64,"match_count":8,"context":"laced by a newer generation of fixation plates introduced to surgeon customers in fiscal year 2020, and an increase of $0.3 million in reserves for increased field inventory in 2020 compared to 2019. Gross margin decreased from 80.6% in 2019 to 78.3% for 2020 primarily due to the increased charges for inventory obsolescence and costs of surgical instruments used during procedures, and the impairment of capitalized surg","filed_date":"2021-04-19","accession":"0001193125-21-120293","full_text":"https://origin.rootz.global/static/filing/0001193125-21-120293.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":64,"match_count":8,"context":"lty expense and an increase of $0.7 million in costs of surgical instruments used during procedures, and $0.1 million impairment of capitalized surgical instruments that no longer have a useful life. Gross margin decreased from 80.6% in 2019 to 78.3% for 2020 primarily due to the increased charges for inventory obsolescence and costs of surgical instruments used during procedures, and the impairment of capitalized surg","filed_date":"2021-03-30","accession":"0001193125-21-100296","full_text":"https://origin.rootz.global/static/filing/0001193125-21-100296.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":60,"match_count":5,"context":"easonable and competitive. Compensation of our executives is structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives. Our named executive officers (NEOs) for fiscal year 2020 were as follows: | | | | John T. Treace, our Chief Executive Officer, Director and Founder; | | | | | | Mark L. Hair, our Chief Financial Officer; | | | | | |","filed_date":"2021-04-19","accession":"0001193125-21-120293","full_text":"https://origin.rootz.global/static/filing/0001193125-21-120293.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"margin_pressure","strength":56,"match_count":7,"context":"istration, some of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in reduced demand for our products or additional pricing pressure. Federal, State and Foreign Fraud and Abuse and Physician Payment Transparency Laws In addition to FDA restrictions on marketing and promotion of drugs and devices, other federal and state laws res","filed_date":"2022-03-04","accession":"0000950170-22-002903","full_text":"https://origin.rootz.global/static/filing/0000950170-22-002903.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":55,"match_count":5,"context":"easonable and competitive. Compensation of our executives is structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives. Our named executive officers (NEOs) for fiscal year 2020 were as follows: | | | | John T. Treace, our Chief Executive Officer, Director and Founder; | | | | | | Mark L. Hair, our Chief Financial Officer; | | | | | |","filed_date":"2021-03-30","accession":"0001193125-21-100296","full_text":"https://origin.rootz.global/static/filing/0001193125-21-100296.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":48,"match_count":1,"context":"a post-operative boot. We also offer other advanced instrumentation and implants for use in the Lapiplasty Procedure or other ancillary procedures performed in high frequency with bunion surgery. No single customer accounted for 10% or more of our revenue during the year ended December 31, 2020. We expect our revenue to increase in absolute dollars in the foreseeable future as we expand our sales territories, new accounts and tr","filed_date":"2021-04-19","accession":"0001193125-21-120293","full_text":"https://origin.rootz.global/static/filing/0001193125-21-120293.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_concentration","strength":48,"match_count":1,"context":"a post-operative boot. We also offer other advanced instrumentation and implants for use in the Lapiplasty Procedure or other ancillary procedures performed in high frequency with bunion surgery. No single customer accounted for 10% or more of our revenue during the year ended December 31, 2020. We expect our revenue to increase in absolute dollars in the foreseeable future as we expand our sales territories, new accounts and tr","filed_date":"2021-03-30","accession":"0001193125-21-100296","full_text":"https://origin.rootz.global/static/filing/0001193125-21-100296.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":40,"match_count":5,"context":"upon this assessment, our Compensation Committee believes that our compensation plans, policies and practices for our NEOs and other employees do not create risks that are reasonably likely to have a material adverse effect on our Company. Compensation Committee Report to Stockholders The Compensation Committee has reviewed and discussed with management the section entitled Compensation Discussion and Analysis containe","filed_date":"2026-04-06","accession":"0001630627-26-000005","full_text":"https://origin.rootz.global/static/filing/0001630627-26-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":40,"match_count":5,"context":"upon this assessment, our Compensation Committee believes that our compensation plans, policies and practices for our NEOs and other employees do not create risks that are reasonably likely to have a material adverse effect on our Company. Compensation Committee Report to Stockholders The Compensation Committee has reviewed and discussed with management the section entitled Compensation Discussion and Analysis containe","filed_date":"2025-04-07","accession":"0000950170-25-051369","full_text":"https://origin.rootz.global/static/filing/0000950170-25-051369.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"1630627/000095017024040228/) **Origin leaf:** 96cbed7cee8dd7bcfde9b412cc9e7e59464867573175a2340e65dfd6a7466edd **Words:** 28,462 **Logo:** https://api.massive.com/v1/reference/company-branding/dHJlYWNlLmNvbQ/images/2025-04-04_logo.png --- DEF 14A 1 tmci_def_14a_2024_for_fi.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to S","filed_date":"2024-04-02","accession":"0000950170-24-040228","full_text":"https://origin.rootz.global/static/filing/0000950170-24-040228.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"1630627/000095017023011691/) **Origin leaf:** 89ece027a85a1965c7762b85c7ca4891383a67cbaff4d2a0fd496797d1cc6de5 **Words:** 25,530 **Logo:** https://api.massive.com/v1/reference/company-branding/dHJlYWNlLmNvbQ/images/2025-04-04_logo.png --- DEF 14A 1 tmci_def_14a_2023.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section","filed_date":"2023-04-04","accession":"0000950170-23-011691","full_text":"https://origin.rootz.global/static/filing/0000950170-23-011691.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"growth_inflection","strength":40,"match_count":5,"context":"and comprehensive loss | | | (4,265 | ) | | | (3,668 | ) | | | (597 | ) | | | 14 | % | | | | | | | | | | | | | | | | | | | | | | * | Not meaningful | | ***Revenue.* Revenue increased $18.0 million, or 45.5%, from $39.4 million in 2019 to $57.4 million in 2020. The increase in revenue was primarily due to an increased number of Lapiplasty Procedure Kits sold and an expanded customer base. *Cos","filed_date":"2021-04-19","accession":"0001193125-21-120293","full_text":"https://origin.rootz.global/static/filing/0001193125-21-120293.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"growth_inflection","strength":40,"match_count":5,"context":"and comprehensive loss | | | (4,265 | ) | | | (3,668 | ) | | | (597 | ) | | | 14 | % | | | | | | | | | | | | | | | | | | | | | | * | Not meaningful | | ***Revenue.* Revenue increased $18.0 million, or 45.5%, from $39.4 million in 2019 to $57.4 million in 2020. The increase in revenue was primarily due to an increased number of Lapiplasty Procedure Kits sold and an expanded customer base. *Cos","filed_date":"2021-03-30","accession":"0001193125-21-100296","full_text":"https://origin.rootz.global/static/filing/0001193125-21-100296.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":37,"match_count":4,"context":"ncial measure that the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs, restructuring costs, customer credit loss, litigation costs, and debt extinguishment loss. For purposes of the 2025 annual incentive plan, the Adjusted EBITDA metric also excludes corporate bonus expense under this annu","filed_date":"2026-04-06","accession":"0001630627-26-000005","full_text":"https://origin.rootz.global/static/filing/0001630627-26-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":36,"match_count":2,"context":"pliers and employees, or under other contractual arrangements, and cause other operational inconveniences. Additionally, any losses or delay in access to funds as a result of such events could have a material adverse effect on our ability to meet contractual obligations, and our financial condition, cash flows and stock price. We also hold short-term high credit quality investments that are managed in accordance with ou","filed_date":"2023-05-09","accession":"0000950170-23-019154","full_text":"https://origin.rootz.global/static/filing/0000950170-23-019154.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":32,"match_count":4,"context":"tain NEOs\" and Notes 5 and 6 below for more information. (3) The column sets forth the number of RSUs granted to our NEOs in 2025. The RSUs vest over four years from the grant date in 25% annual installments on the first four anniversaries of the grant date, subject to the applicable NEOs continued service through each applicable vesting date. See the section above entitled \"Compensation Discussion a","filed_date":"2026-04-06","accession":"0001630627-26-000005","full_text":"https://origin.rootz.global/static/filing/0001630627-26-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":32,"match_count":4,"context":"ncial measure that the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs, restructuring costs, customer credit loss, litigation costs, and debt extinguishment loss. For purposes of the 2024 annual incentive plan, the Adjusted EBITDA metric also excludes the costs of bonus payments under this","filed_date":"2025-04-07","accession":"0000950170-25-051369","full_text":"https://origin.rootz.global/static/filing/0000950170-25-051369.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":32,"match_count":4,"context":"Mr. Bakewell has also previously served at Interline Brands, Inc., RegionalCare Hospital Partners, Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020, Cyberonics, Inc., now part of LivaNova PLC (NASDAQ:LIVN), Altra Energy Technologies, Inc. and ZEOS International, Ltd. Mr. Bakewell has served as a member of the board of directors of Neuronetics, Inc. (NA","filed_date":"2024-04-02","accession":"0000950170-24-040228","full_text":"https://origin.rootz.global/static/filing/0000950170-24-040228.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":32,"match_count":4,"context":"Mr. Bakewell has also previously served at Interline Brands, Inc., RegionalCare Hospital Partners, Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020, Cyberonics, Inc., now part of LivaNova PLC (NASDAQ:LIVN), Altra Energy Technologies, Inc. and ZEOS International, Ltd. Mr. Bakewell has served as a member of the board of directors of Neuronetics, Inc. (NA","filed_date":"2023-04-04","accession":"0000950170-23-011691","full_text":"https://origin.rootz.global/static/filing/0000950170-23-011691.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":32,"match_count":4,"context":"Mr. Bakewell has also previously served at Interline Brands, Inc., RegionalCare Hospital Partners, Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020, Cyberonics, Inc., now part of LivaNova PLC (NASDAQ:LIVN), Altra Energy Technologies, Inc. and ZEOS International, Ltd. Mr. Bakewell has served as a member of the board of directors of Neuronetics, Inc. (NA","filed_date":"2022-04-04","accession":"0000950170-22-005330","full_text":"https://origin.rootz.global/static/filing/0000950170-22-005330.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":32,"match_count":4,"context":"n or entity other than the Corporation with respect to any direct or indirect compensation or reimbursement for service as a director of the Corporation that has not been disclosed therein and (B) if elected as a director of the Corporation, will comply with all applicable corporate governance, conflict of interest, confidentiality, stock ownership and trading and other policies and guidelines of the Corporation appli","filed_date":"2021-04-27","accession":"0001193125-21-134507","full_text":"https://origin.rootz.global/static/filing/0001193125-21-134507.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":28,"match_count":1,"context":"ror or fraud may occur and not be detected. 26 PART IIOTHER INFORMATION Item 1. Legal Proceedings. Except as described below, we are not a party to any legal proceedings which we believe would have a material adverse effect on our business or results of operations. From time to time, we may become involved in various legal proceedings that arise in the ordinary course of our business. On April 11, 2025, a shareholder fi","filed_date":"2026-08-07","accession":"0001630627-26-000018","full_text":"https://origin.rootz.global/static/filing/0001630627-26-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":24,"match_count":3,"context":"sted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs, restructuring costs, customer credit loss, litigation costs, and debt extinguishment loss. Non-GAAP financial measures such as Adjusted EBITDA are presented in addition to, and not as a substitute for, or superior to, f","filed_date":"2026-02-27","accession":"0001193125-26-079163","full_text":"https://origin.rootz.global/static/filing/0001193125-26-079163.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":24,"match_count":3,"context":"sted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs, restructuring costs, customer credit loss, litigation costs, and debt extinguishment loss. Non-GAAP financial measures such as Adjusted EBITDA are presented in addition to, and not as a substitute for, or superior to, f","filed_date":"2025-11-06","accession":"0001193125-25-269481","full_text":"https://origin.rootz.global/static/filing/0001193125-25-269481.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":24,"match_count":3,"context":"sted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs, restructuring costs, customer credit loss, litigation costs, and debt extinguishment loss. Non-GAAP financial measures such as Adjusted EBITDA are presented in addition to, and not as a substitute for, or superior to, f","filed_date":"2025-08-07","accession":"0000950170-25-105039","full_text":"https://origin.rootz.global/static/filing/0000950170-25-105039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"growth_inflection","strength":24,"match_count":3,"context":"er and Board Member of Treace. “Looking ahead, our expanding best in class bunion portfolio and robust innovation pipeline along with significant surgeon training momentum positions Treace for accelerating growth throughout the year and to extend our leadership position within the US bunion market.” First Quarter 2025 Financial Results Revenue for the first quarter of 2025 was $52.6 million, representi","filed_date":"2025-05-08","accession":"0000950170-25-066915","full_text":"https://origin.rootz.global/static/filing/0000950170-25-066915.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"TMCI","company":"TREACE MEDICAL CONCEPTS, INC.","exchange":"Nasdaq","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":24,"match_count":3,"context":"sted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs, restructuring costs, customer credit loss, litigation costs, and debt extinguishment loss. Non-GAAP financial measures such as Adjusted EBITDA are presented in addition to, and not as a substitute for, or superior to, f","filed_date":"2025-02-27","accession":"0000950170-25-029009","full_text":"https://origin.rootz.global/static/filing/0000950170-25-029009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"f5b41a313f746e5c1c3e9b5666ec0cea84d5146b98a2982e37891572065b29f3","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"f42b03191b43deb5c2916cf35a096de06f617655e7be67e2e493750f0e58b8cb","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":470,"hourly_limit":500,"remaining":30,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}